Purple Biotech Ltd.
Symboli: PPBT
NASDAQ
0.67
USDMarkkinahinta tänään
-0.6555
P/E-suhde
0.0000
PEG-suhde
17.38M
MRK Cap
- 0.00%
DIV Tuotto
Purple Biotech Ltd. (PPBT) Tilinpäätöstiedotteet
Tase
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 15.4 | 32.1 | 47.2 | |||||||||||
balance-sheet.row.short-term-investments | 0 | 0.9 | 17.1 | 36.3 | |||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-current-assets | 0 | 0.4 | 1.1 | 1.3 | |||||||||||
balance-sheet.row.total-current-assets | 0 | 15.8 | 33.3 | 48.5 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0.5 | 0.7 | 0.9 | |||||||||||
balance-sheet.row.goodwill | 0 | 28 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 20.7 | 20.5 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 28 | 20.7 | 20.5 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0.2 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0.2 | |||||||||||
balance-sheet.row.total-non-current-assets | 0 | 28.5 | 21.4 | 21.7 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 0 | 44.3 | 54.6 | 70.2 | |||||||||||
balance-sheet.row.account-payables | 0 | 3.5 | 2.1 | 1.5 | |||||||||||
balance-sheet.row.short-term-debt | 0 | 0.2 | 0.2 | 0.2 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0.2 | 0.3 | 0.6 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 0 | 3.5 | 4.7 | 2.6 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 2.8 | 0.5 | 0.8 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0.2 | 0.5 | 0.7 | |||||||||||
balance-sheet.row.total-liab | 0 | 10 | 7.5 | 5.1 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | 0 | -137.5 | -117.6 | -95.9 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 38.5 | 10.1 | 8.8 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 133.2 | 154.4 | 152 | |||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 34.2 | 46.9 | 64.8 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 44.3 | 54.6 | 70.2 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0.1 | 0.2 | 0.3 | |||||||||||
balance-sheet.row.total-equity | 0 | 34.3 | 47.1 | 65.1 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||
Total Investments | 0 | 0.9 | 17.1 | 36.5 | |||||||||||
balance-sheet.row.total-debt | 0 | 0.4 | 0.5 | 0.7 | |||||||||||
balance-sheet.row.net-debt | 0 | -14.1 | -14.5 | -10.1 |
Kassavirtalaskelma
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -19.9 | -21.8 | -17.8 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0.2 | 0.2 | 0.2 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | -0.8 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | 1.9 | 2.4 | 2.1 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | 0.3 | 3.3 | 0.6 | |||||||||||
cash-flows.row.account-receivables | 0 | 0.2 | 0.3 | -0.3 | |||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0.6 | |||||||||||
cash-flows.row.account-payables | 0 | 1.3 | 0.8 | 0.3 | |||||||||||
cash-flows.row.other-working-capital | 0 | -1.2 | 2.1 | 0 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | -0.9 | -0.8 | -0.1 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.2 | -0.1 | |||||||||||
cash-flows.row.acquisitions-net | 0 | -3.5 | 0 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 16.7 | 19.8 | 13.2 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0.3 | 0.4 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 13.1 | 19.9 | 13.4 | |||||||||||
cash-flows.row.debt-repayment | 0 | -0.2 | -0.2 | -0.2 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 5.7 | 1.5 | 0.6 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 0 | -0.9 | -0.2 | 1.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 5.5 | 1.1 | 1.5 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0.1 | -0.2 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | -0.5 | 4.1 | -0.4 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 14.5 | 15 | 10.9 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 15 | 10.9 | 11.2 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | -19.2 | -16.7 | -15.1 | |||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.2 | -0.1 | |||||||||||
cash-flows.row.free-cash-flow | 0 | -19.2 | -17 | -15.2 |
Tuloslaskelmarivi
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | -0.9 | -0.3 | |||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0.2 | 0.2 | 0.2 | |||||||||||
income-statement-row.row.gross-profit | 0 | -0.2 | -1.1 | -0.6 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 0 | 22.1 | 22.6 | 17.9 | |||||||||||
income-statement-row.row.cost-and-expenses | 0 | 22.3 | 22.6 | 17.9 | |||||||||||
income-statement-row.row.interest-income | 0 | 0.5 | 1 | 0.3 | |||||||||||
income-statement-row.row.interest-expense | 0 | 2.2 | 0.1 | 0.2 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 2.3 | 0.8 | 0.1 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | 0 | 2.3 | 0.8 | 0.1 | |||||||||||
income-statement-row.row.interest-expense | 0 | 2.2 | 0.1 | 0.2 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0.2 | 1.2 | 0.6 | |||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 0 | -22.3 | -22.6 | -17.9 | |||||||||||
income-statement-row.row.income-before-tax | 0 | -20 | -21.8 | -17.8 | |||||||||||
income-statement-row.row.income-tax-expense | 0 | -0.1 | -0.9 | 0.6 | |||||||||||
income-statement-row.row.net-income | 0 | -19.9 | -20.8 | -18.5 |
Usein kysytty kysymys
Mikä on Purple Biotech Ltd. (PPBT) taseen loppusumma?
Purple Biotech Ltd. (PPBT) kokonaisvarat ovat 44302000.000.
Mikä on yrityksen vuotuinen liikevaihto?
Vuotuinen liikevaihto on N/A.
Mikä on yrityksen voittomarginaali?
Yrityksen voittomarginaali on 0.000.
Mikä on yrityksen vapaa kassavirta?
Vapaa kassavirta on -0.807.
Mikä on yrityksen nettovoittomarginaali?
Nettovoittomarginaali on 0.000.
Mikä on yrityksen kokonaistulot?
Kokonaisliikevaihto on 0.000.
Mikä on Purple Biotech Ltd. (PPBT) nettovoitto (nettotulos)?
Nettovoitto (nettotulos) on -19880000.000.
Mikä on yrityksen kokonaisvelka?
Kokonaisvelka on 351000.000.
Mikä on yrityksen toimintakulujen määrä?
Toimintakulut ovat 22072000.000.
Mikä on yrityksen kassan määrä?
Yrityksen kassavarat ovat 0.000.